Quality · Good distribution practice

Returns from a distant market, and what you can actually take back

By LNJC· · 6 min read

A manufacturer should expect returned pharmaceutical products to be quarantined on receipt, kept under their storage conditions, and destroyed unless a critical, risk-based assessment shows their quality is satisfactory, according to WHO Technical Report Series No. 1025, Annex 7. The agreement between the parties should settle in advance how returns are handled, and every decision should be recorded.

Quarantine on receiptfor all returned medical products, with access and distribution prevented until a decision is taken (WHO TRS 1025, Annex 7, 9.2)
Destroy unless certainreturned products are destroyed unless it is certain their quality is satisfactory (WHO TRS 1025, Annex 7, 9.3)
Records of allreturned, rejected and destroyed products, kept for a defined period (WHO TRS 1025, Annex 7, 9.8)

What happens to a pharmaceutical product when it is returned?

It goes into quarantine and stays there until someone authorised decides its fate. Section 9 of WHO Technical Report Series No. 1025, Annex 7, Good storage and distribution practices for medical products (2020), says returned medical products should be handled in accordance with authorized procedures, and that all returned medical products should be placed in quarantine upon receipt.1

Section 9.2 is specific about what quarantine means. The status of the goods should be clear, precautions should be taken to prevent access and distribution until a decision has been taken on their disposition, and the particular storage conditions applicable to the products should be maintained until that decision.1

Destroy or reissue returned goods: which is the default?

Destruction is the default, and reissue is the exception that has to be earned. Section 9.3 of WHO Technical Report Series No. 1025, Annex 7, says medical products returned should be destroyed unless it is certain that their quality is satisfactory, after they have been critically assessed in accordance with a written and authorized procedure.1

Section 9.4 sets the bar for that certainty. The nature of the product, any special storage conditions it requires, its condition and history, and the time lapse since it was issued should all be taken into account. Where any doubt arises over the quality of the product, it should not be considered suitable for reissue or reuse, and any action taken should be appropriately recorded.1

That is the honest answer to "what can you actually take back". The WHO text does not say returned goods can be taken back into the exporter's stock. It describes a decision about the product, with doubt resolved against reuse.

What does a risk-based assessment of returned medical products consider?

The product, its history and, for a distant market especially, the journey back. Section 9.5 of WHO Technical Report Series No. 1025, Annex 7, says a risk-based process should be followed when deciding on the fate of returned goods, and that this should include, but not be limited to, the nature of the product, storage conditions, condition of the product history, time-lapse since distribution, and the manner and condition of transport while being returned.1

The last item matters most on a long lane: if the return journey cannot show that storage conditions were kept, section 9.4 leaves little room, because doubt means no reissue. For what that evidence should look like, see temperature excursion evidence.

Section 9.5 also says the goods should be examined, with decisions taken by suitably qualified, experienced and authorized persons.1

Why should the agreement between the parties settle returns in advance?

Because the WHO text makes the agreement part of the decision. Among the considerations section 9.5 lists for handling returned goods are the terms and conditions of the agreement between the parties.1 Our reading is that a manufacturer and its distributor should therefore write their returns arrangements into that agreement before the first shipment, rather than work them out when a consignment is already in quarantine.

The WHO text does not say who bears the cost of a return, or fix a return window. It is common industry practice to settle such points in the agreement: which returns are accepted, who pays for assessment, and whether rejected stock is shipped back or destroyed where it is. For the wider contract, see distribution agreement essentials.

How should rejected and destroyed products be handled and recorded?

Under authorised procedures, with the environment in mind, and with records kept. Section 9.6 of WHO Technical Report Series No. 1025, Annex 7, says that where products are rejected, authorized procedures should be followed, including safe transport. Section 9.7 says destruction should be done in accordance with international, national and local requirements regarding disposal of such products, and with due consideration to the protection of the environment.1

Section 9.8 closes the loop: records of all returned, rejected and destroyed medical products should be kept for a defined period, in accordance with national requirements.1 Where a return is part of a quality problem rather than a commercial one, the recall route applies instead; see recalling a batch you have already exported.

How does this apply to returns from the Republic of Yemen?

The WHO text above is an international baseline, not a statement of what the Republic of Yemen requires or permits for returns or for destruction. Local specifics are confirmed case by case. Agree the returns process with your partner using section 9 as the common reference. For the wider market picture, see entering the Yemen market, and for vetting the partner who will hold that stock, qualifying a distributor.

Frequently asked questions

What should a manufacturer expect when pharmaceutical products are returned from an export market?

Under WHO Technical Report Series No. 1025, Annex 7, returned medical products are placed in quarantine on receipt, kept under their storage conditions, and destroyed unless a critical assessment under a written procedure shows their quality is satisfactory. The decision follows a risk-based process and the agreement between the parties, and every action is recorded.

Can returned pharmaceutical products be put back into stock?

WHO Technical Report Series No. 1025, Annex 7, section 9.3 says returned products should be destroyed unless it is certain that their quality is satisfactory, after a critical assessment. Section 9.4 adds that where any doubt arises over quality, the product should not be considered suitable for reissue or reuse. The guidance does not describe taking goods back into the exporter's stock.

Does the WHO guidance set a time limit for returns?

No. Section 9 of WHO Technical Report Series No. 1025, Annex 7, names the time lapse since issue or distribution as one factor in the assessment, but sets no time limit for returns and does not say who bears the cost. Those points are for the manufacturer and the distributor to settle in their agreement.

What records should be kept for returned goods?

Section 9.8 of WHO Technical Report Series No. 1025, Annex 7, says records of all returned, rejected and destroyed medical products should be kept for a defined period, in accordance with national requirements. Section 9.4 adds that any action taken on a returned product should be appropriately recorded.

References

  1. World Health Organization, Good storage and distribution practices for medical products, WHO Technical Report Series No. 1025, Annex 7, Fifty-fourth report (2020), section 9 Returned goods, sections 9.1 to 9.8. Accessed 29 October 2026. cdn.who.int